ClinicalTrials.gg
RecruitingNCT05436795Updated Oct 23, 2023

A Randomized Controlled Trial of a Digital, Self-testing Strategy for COVID-19 Infection in South Africa.

A Phase 1/2 interventional study of Abbott Panbio rapid antigen self-tests and COVIDSmart CARE! app in COVID-19, sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre. Recruiting at 1 site in South Africa. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-23.

Sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre · Phase 1/2, Interventional, and Screening

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2023, 2 years 11 months ago, but the record still lists the study as recruiting.
  • Started Feb 2023; still recruiting 3 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
600
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in COVID-19 by McGill University Health Centre/Research Institute of the McGill University Health Centre — 2 open to participants now, 2 under way, none of them phase 3. COVID-19 · McGill University Health Centre/Research Institute of the McGill University Health Centre.

Planned enrollment
3rd of 11
600 · median 132
Started
2023
the only one that year
Phase 1/2
Only one
of the 12
Registered
11th of 12
by date

Among the 12 studies in COVID-19 by McGill University Health Centre/Research Institute of the McGill University Health Centre, this one is the 3rd largest by planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2023, is the only one in phase 1/2, and was the 11th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

2 of the 12 studies in COVID-19 by McGill University Health Centre/Research Institute of the McGill University Health Centre are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in COVID-19 by McGill University Health Centre/Research Institute of the McGill University Health Centre, or all of them as a file.
02

Study summary

As the world opens up to rapidly increasing vaccination coverage and newer variants, there is an even greater need for timely access to at-home COVID-19 testing, or self-testing based out of kiosks, offices, or private spaces.

Data on digital strategies that complement self-testing are sparse. Using a superiority randomized controlled trial design (open-label, single-blinded), the investigators will aim to evaluate the impact of a digital self-testing strategy offered out of kiosks/private spaces on the turnaround time to test results, the proportion of participants initiated on action plans, and new infection detected with the strategy. The investigators will compare these outcomes to a conventional lab-based strategy.

Significance:

A digital, portable, self-testing strategy will facilitate rapid self-knowledge of COVID-19 status and rapid classification into clinical/quarantine/prevention plans.

The study will document the impact of a digitally connected self-testing strategy for COVID-19 infection. Upon completion of the strategy, the digital program will be available for global dissemination.

Read the detailed description

The investigators hypothesize that a rapid digital self-testing strategy that evaluates the risk of severe COVID-19 infection and guides participants on the methods of self-test interpretation and ensuing action plans will be more impactful in detecting COVID-19 infection and will facilitate more participants to take an appropriate course of action compared to the conventional strategy. Action plans initiated will be either: a) clinical care, b) prevention (home quarantine, isolation), or c) social distancing. Taken together, these actions will impact health outcomes during the current and ensuing SARS-CoV-2 surges.

Using a superiority randomized controlled trial (RCT) design, the investigators will randomize participants to either the App-based self-testing arm or the conventional testing arm (screening and testing performed by a health care worker (HCW) at the COVID-19 testing site). A confirmatory RT-PCR test will be performed in both arms. The standard of care will be offered in the conventional arm.

The interventional strategy will be offered in kiosks/private spaces within COVID-19 testing sites or student health clinics. The COVIDSmart CARE! digital App-based program will be downloaded onto the test kiosk based tablets or participants' smartphones. This strategy will yield self-test results and guided action plans in a rapid turnaround time.

03

Conditions studied

  • COVID-19

Browse trials for

Keywords

  • COVID-19
  • self-test
  • self-sample
  • point-of-care
  • randomized controlled trial
  • rapid test
  • digital
  • app-based
  • SARS-CoV-2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 years and above
  • All sexes and genders
  • Suspecting COVID-19 exposure
  • Symptomatic or asymptomatic for COVID-19
  • Mental capacity to provide
  • Access to internet connectivity and digitally literate
  • Access to a smart device that can download and run the COVIDSmart CARE! App (e.g., Android tablet version 6 or higher).

Exclusion criteria

Exclusion Criteria:

  • Participants with serious mental health or clinical condition which limits their capacity to provide .
  • Those with apparent severe COVID-19 symptoms requiring urgent hospitalization (e.g., severe shortness of breath, impaired level of consciousness, etc.).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Screening
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
600 participants (estimated)

Study arms

  • Experimental
    Interventional Arm

    In the interventional arm, we will offer a self-administered supervised COVID-19 testing strategy with an investigational device - Abbott's Panbio COVID-19 Antigen Self-test. The self-test process will be facilitated by the COVIDSmart CARE! digital App and platform. Suspected COVID-19 patients will be triaged into one of three action plans: a) clinical care pathways, b) prevention (home quarantine, isolation) pathways, or c) social distancing.

    Device: Abbott Panbio rapid antigen self-tests · Other: COVIDSmart CARE! app

  • No intervention
    Conventional Arm

    Participants presenting to test for SARS-CoV-2 will be staged on their self-reported severity of symptoms (mild, moderate, severe) and tested with rapid antigen tests, followed by RT-PCR testing. Suspected COVID-19 patients will be triaged into one of three action plans: a) clinical care pathways, b) prevention (home quarantine, isolation) pathways, or c) social distancing. Conventional arm is the standard of care arm.

Interventions

  • DeviceAbbott Panbio rapid antigen self-tests

    COVID-19 self-testing will be performed using investigational Abbott Panbio rapid antigen self-test kits that require self-sampled nasal swabs.

  • OtherCOVIDSmart CARE! app

    Guided by the application that connects, educates, and communicates a digital, contactless open access strategy, participants will have the opportunity to self-test and assess their risk level of COVID-19 infection, as well as the option to refer their close contacts to testing for those who are COVID-19 positive, through the study platform.

06

What researchers measure

Primary outcomes

  1. Estimating the impact on turnaround time (TAT) from the point of taking a test to initiating a clinical action plan.

    TAT is estimated to be \<2 hours compared to 24 hours taken with a conventional RT-PCR test.

    Time frame: Less than 24-48 hours

Secondary outcomes

  1. The impact of the COVIDSmart CARE! self-testing strategy on the proportion of participants taking an appropriate COVID-19 related action compared to conventional COVID-19 testing strategies at 24 hours post randomization.

    Proportional estimates of participants who action the guidance given via the App compared to those who undergo standard of care testing will measure the efficacy of the App on changing behaviour and/or linkage to care.

    Time frame: Less than 24-48 hours

  2. Impact on detection of new COVID-19 infections in each arm.

    We will document the impact of digital self-testing versus conventional testing on the number of new COVID-19 infections detected in each arm. We will compare and document the proportion of newly identified participants as test positives in both arms. Test positives and test negatives will be confirmed by lab confirmed results and test protocols.

    Time frame: 1 year

Other outcomes

  1. Diagnostic accuracy of COVIDSmart CARE! versus conventional reference standard.

    We will compare the diagnostic performance of our interventional (digital self-testing strategy) versus conventional RT-PCR tested (a composite reference standard algorithm containing NAATs from a different manufacturer); with performance metrics (i.e., sensitivity, specificity, and positive and negative predictive values with 95% CI).

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
  • University of Cape Town Lung Institute
    Cape Town, Western Cape 7700, South Africa
    Recruiting
    • Keertan Dheda, MBBCh, PhD · Contactkeertan.dheda@uct.ac.za · 021 442 1816
    • Ali Esmail, MD · Contactali.esmail@uct.ac.za
    • Keertan Dheda, MBBCh, PhD · Principal investigator
    • Ali Esmail, MD · Sub investigator
    • Apoorva Anand, BDS, MScPH · Sub investigator
    • Jeremi Swanepoel, MBChB, MSc · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Dec 2023, 10 months after the start.

Of 107 non-industry phase 1/2 interventional studies under COVID-19, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 21. This study's planned 10 months is close to that.

Counting every sponsor, half of 187 studies reached it within 11 months; a quarter within 4 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2022
First posted
Jun 29, 2022
StartActual
Feb 2, 2023
Primary completionEst.
Dec 2023
CompletionEst.
Mar 2024
Last update
Oct 23, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 23, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05436795
Collaborators
University of Cape Town Lung Institute
Responsible party
Nitika Pai (Associate Professor, McGill University Health Centre/Research Institute of the McGill University Health Centre) — Principal investigator
First posted
Jun 29, 2022
Start date
Feb 2, 2023
Primary completion
Dec 2023 (estimated)
Completion
Mar 2024 (estimated)
Last update
Oct 23, 2023

Study contacts

Keertan Dheda, MBBCh, PhD
Contact
keertan.dheda@uct.ac.za
021 442 1816
Ali Esmail, MD
Contact
ali.esmail@uct.ac.za
021 442 1816
Nitika Pant Pai, MD, MPH, PhD
principal investigator · McGill University Health Centre Research Institute, Montreal, Canada

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion